Reduced nitric oxide synthase and cyclo-oxygenase activity in the uterus of non-obese diabetic mice

Valeria Roca, Luciana Larocca, Mario Calafat, Julieta Aisemberg¹, Roberto Meiss², Ana M Franchi¹ and Claudia Pérez Leirós

Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, CONICET, Buenos Aires, Argentina, ¹Centro de Estudios Farmacológicos y Botánicos (CEFyBO), Universidad de Buenos Aires, CONICET, Buenos Aires, Argentina and ²Academia Nacional de Medicina, Buenos Aires, Argentina

Correspondence should be addressed to C P Leirós who is now at Ciudad Universitaria, Pab. II, 4° piso, 1428 Buenos Aires, Argentina; Email: cpleiros@qb.fcen.uba.ar

Abstract

A functional interaction between progesterone, Th2 cytokines and a suitable balance between nitric oxide and prostaglandins in the uterus is considered to have a major role in the success of embryo implantation and pregnancy. Non-obese diabetic (NOD) mice offer a suitable model to study the modulatory role of Th1 cytokines on uterus signalling and function, since at the prediabetic stage they develop a spontaneous Th1 autoimmune response against exocrine glands similar to Sjögren's syndrome. Vasoactive intestinal peptide (VIP) is a vasoactive neuro- and immunopeptide that promotes Th2 profiles and contributes to the smooth muscle relaxation and vasodilation. The aim of the present study was to investigate the activities of nitric oxide synthase and cyclo-oxygenase and the effect of VIP in the uterus of NOD mice with an emerging Th1 cytokine response. We present evidence of a reduced basal and VIP-stimulated activity of both enzymes in the uterus of NOD mice compared with normal BALB/c mice in proestrus. An altered functional interaction between both enzymes is also present in NOD mice at the time when increased levels of serum interleukin (IL)-12 and tumour necrosis factor- α but not interferon (IFN)- γ or IL-10 were detected. We conclude that signalling alterations *in uteri* of NOD mice are simultaneous to the onset of a systemic Th1 cytokine response.

Reproduction (2006) **132** 931–938

Introduction

Among the key factors that contribute to the success of embryonic implantation and pregnancy, progesterone levels, a Th2 cytokine profile and a suitable balance between nitric oxide and prostaglandins in the uterus have been assigned a critical role. Progesterone is central to the progression of the oestrous cycle and to the receptivity of the endometrium for embryo implantation. It is also known to modulate the Th1/Th2 cytokine profile in favour of Th2 cytokines (Szekeres-Bartho 2002). In line with this, patients with Th1 autoimmune diseases such as multiple sclerosis and rheumatoid arthritis improve during pregnancy (Nelson & Ostensen 1997, Cutolo 2000, Olsen & Kovacs 2002).

It has been proposed that optimal levels of nitric oxide are needed for implantation (Chwalisz *et al.* 1996, Purcell *et al.* 1999, Chwalisz & Garfield 2000) and the establishment of pregnancy (Chwalisz *et al.* 1999). While nitric oxide synthase (NOS) immunoreactivity increases in rat endometrial and glandular epithelium in the periovulatory period contributing to uterine

quiescence (Chatterjee *et al.* 1996, Ota *et al.* 1999), excessively high amounts are shown to impair embryo implantation causing embryonic resorption processes (Ogando *et al.* 2003). Constitutive NOS isoforms are activated by several physiological stimuli resulting in the production of low amounts of nitric oxide, while it is synthesized in vast amounts by the inducible NOS isoform (NOS II) upon the elicitation of inflammatory mediators (Moncada *et al.* 1991, MacMicking *et al.* 1997). The mechanism for nitric oxide regulation of implantation is still unclear, but recent supportive evidence indicates that it could act through the regulation of metalloproteases (Zhang *et al.* 2004) and cyclo-oxygenases (Wang & Dey 2005), or by directly reducing uterine contractility (Bullelli & de Ziegler 2005, Wang & Dey 2005). A mutual regulation between nitric oxide synthase and cyclo-oxygenase (COX) in uterine tissue from mouse (Cella *et al.* 2006) and rat (Ribeiro *et al.* 2003) has been also shown.

The non-obese diabetic (NOD) mouse is a suitable model to study the progressive loss of exocrine secretion

characteristic of Sjögren's syndrome, a chronic autoimmune disease that affects women in a 9:1 ratio. In the prediabetic stage, female mice of this strain provide a valuable tool to study the initiation and progression of the disease, since they display a progressive loss of salivary and lacrimal secretion and a spontaneous Th1 autoimmune response against exocrine glands (Robinson *et al.* 1996, van Blokland & Versnel 2002). We have recently shown a loss of NOS activation in exocrine glands of prediabetic female NOD mice that parallels salivary dysfunction together with a lower response to vasoactive intestinal peptide (VIP) (Rosignoli *et al.* 2004, 2005).

Among various stimuli known to increase nitric oxide production thus modulating uterus quiescence, VIP might have an interesting role in some clinical situations where an inflammatory autoimmune disease underlies the course of pregnancy. Actually, VIP, a neuro- and immunopeptide that promotes secretion in glandular epithelium (Ekström *et al.* 1983, Inoue *et al.* 1985), contributes to the smooth muscle relaxation and vasodilation in the uterus through nitric oxide production (Clark *et al.* 1981, Jovanovic *et al.* 1998) and, similar to progesterone, it promotes Th2 cytokine production (Delgado *et al.* 2002). VIP acts through stimulation of constitutive NOS activity, prostaglandin-mediated pathways and cAMP to inhibit uterine contractility (Ottesen *et al.* 1982, Murthy *et al.* 1993). In addition, VIP participates in the maternal regulation of embryonic growth (Gressens *et al.* 1998, Spong *et al.* 1999).

The aim of the present study was to investigate the activities of NOS and COX, two major enzymes involved in uterus function, in prediabetic NOD mice and the effect of VIP on both enzymes. We present evidence of a reduced basal and VIP-stimulated activity of both enzymes in the uterus of NOD mice in proestrus compared with normal BALB/c mice. The effect was coincident with an emerging Th1 cytokine profile in the serum but not in the uterus of NOD mice.

Materials and Methods

Animals

NOD and BALB/c female mice were bred and maintained at the Central Animal Care facility of the School of Exact and Natural Sciences, University of Buenos Aires. They were maintained on a 12 h light:12 h darkness schedule. Normally cycling non-pregnant mice of 15–16 weeks were fasted overnight with water *ad libitum* before being killed; tissues and blood were obtained and processed immediately after. For some experiments younger (10 weeks old) female mice were used. Mice were routinely tested for blood glucose levels (Wiener Lab., Rosario, Argentina) and considered pre-diabetic as their values of serum glucose on two occasions over a 24 h period did not significantly differ from those of the control mice (1.0 ± 0.1 g/l, $n=23$). All studies were

conducted according to standard protocols of the Animal Care and Use Committee of the School of Exact and Natural Sciences, University of Buenos Aires.

Nitric oxide synthase activity

NOS activity was measured *in uteri* using L-[U- 14 C]arginine as substrate as described earlier (Rosignoli *et al.* 2004). Each uterine horn was incubated separately with 0.2 μ Ci L-[U- 14 C]arginine (Amersham Pharmacia Biotech, about 300 mCi/mmol) in 500 μ l Krebs–Ringer bicarbonate (KRB) solution pH 7.4 gassed with 5% CO₂ in O₂ at 37 °C for 30 min. Then tissues were homogenized in 20 mM Hepes pH 5.5 with 0.5 mM EDTA, 1 mM dithiothreitol (DTT) and 0.5 mM EGTA, centrifuged at 10 000 *g* for 10 min and [14 C] citrulline in the supernatants was separated by ion exchange chromatography on AG 50 W resin (Bio-Rad). NOS activity was calculated as total activity minus that measured in the presence of 500 μ M L-N^G-monomethyl arginine (L-NMMA) (Sigma). When used, VIP was added to one horn in the last 15 min at the final concentrations indicated and compared with the basal value of the other uterine horn in the absence of stimulus.

Prostaglandin determination

Prostaglandin E2 (PGE2) was quantified by specific RIA using rabbit antiserum (Sigma Chemical Co.) as previously described (Jaffe & Behrman 1974). The sensitivity of the assay was 5–10 pg/ml and the cross-reactivity was less than 0.1% with other prostaglandins. Intra- and inter-assay variations were each <8.0%. Results were expressed as nanograms prostaglandins synthesized during 1 h/mg protein. Briefly, uterus containing both myometrium and endometrium was removed, immediately cleaned of fat and rinsed thoroughly in cold Krebs–Ringer bicarbonate buffer (KRB) for PGE2 determination. Uterus from each mouse was incubated in a KRB buffer for 60 min at 37 °C and prostaglandins extracted by previous acidification of the supernatant to pH 3 with 1 N HCl. After being extracted twice with 2 ml ethyl acetate, prostaglandins were dried under nitrogen, resuspended in RIA buffer and measured immediately. An aliquot of homogenized uteri was used for measuring the total protein content. When used, VIP was added from the beginning of the incubation time at the final concentrations indicated.

Immunoblotting

Uteri were excised out and individually homogenized at 4 °C in 50 mM Tris–HCl buffer pH 7.5 with 0.15% Triton X-100 and protease inhibitors as previously reported for exocrine tissues (Rosignoli & Perez Leiros 2002). Once centrifuged at 5000 *g* 10 min at 4 °C, supernatants were frozen at –80 °C until used and an aliquot of each

sample was separated for protein determination. Extracts (100 µg protein/lane), positive controls and molecular weight standards (Amersham Pharmacia Biotech Inc.) were subjected to 7.5% SDS-PAGE, transferred to nitrocellulose membranes and revealed with specific monoclonal antibodies against NOS I, NOS II or NOS III (BD, Transduction Labs, KY, USA) or subjected to 10% SDS-PAGE, transferred and revealed with MAB against COX-1 and polyclonal antibody against COX-2 (Santa Cruz, CA, USA) using biotinylated secondary antibodies and streptavidin–peroxidase complex (DAKO), as we have described earlier (Rosignoli *et al.* 2004).

Immunohistochemistry

Uteri from NOD and BALB/c mice were fixed in 4% paraformaldehyde overnight at 4 °C. The tissues were embedded in paraffin wax and sections of 4 µm were cut and placed on silanized glass slides. The immunoperoxidase staining kit Ldab2 (DAKO) was used according to the protocol recommended by the manufacturer. Briefly, tissue sections were de-paraffinized, rehydrated in buffer, endogenous peroxidase activity of the tissues was quenched with 0.1% hydrogen peroxide in methanol for 30 min. The sections were incubated overnight at room temperature with the primary antibodies diluted 1:250 for NOS isoforms and COX-2, and 1:400 for COX-1 in PBS. Control sections without primary antibody served as control. Biotinylated secondary antibodies were added and the sections incubated for 1 h. The sections were then incubated with streptavidin peroxidase complex for 30 min and sections were washed 3 times for 5 min in PBS. Finally, diaminobenzidine (DAKO) was used as the peroxidase substrate, and the tissue sections were counterstained with haematoxylin.

Cytokine measurements

Serum from each animal was isolated by centrifugation at 900 *g* 10 min at 4 °C and stored at –80 °C until used. Uteri were excised out and individually homogenized at 4 °C in 50 mM Tris–HCl buffer pH 7.5 with protease inhibitors. Once centrifuged at 5000 *g* for 10 min at 4 °C, supernatants were frozen at –80 °C until used and an aliquot of each sample was separated for protein determination. Cytokines were determined with a capture ELISA assay as previously described (Juarranz *et al.* 2004). Briefly, microtitre plates (Corning Inc., New York, USA) were coated with a capture monoclonal anti-mouse IL-10, TNF- α , IL-12 or IFN γ antibody (Pharmingen, San Diego, CA, USA) at 2 µg/ml at 4 °C. After washing and blocking with PBS containing 3% BSA, sera were added for 12 h. Unbound material was washed off and biotinylated monoclonal anti-IL-10, TNF- α , IL-12 or IFN- γ antibodies (Pharmingen) were added at 2 µg/ml for 45 min and revealed with

avidin–peroxidase and ABTS substrate solution (Sigma). The intra- and inter-assay variability for cytokine determination was <5%. The detection limits for serum samples were 15 pg/ml for IL-10 and TNF- α and 30 pg/ml for IL-12 and IFN γ ; the values were expressed in picograms per millilitre of serum. The detection limit for tissue samples was 5 pg/mg protein for all cytokines.

Statistical analysis

Statistical significance of differences was determined by the two-tailed *t*-test for independent populations. When multiple comparisons were necessary, the Student–Newman–Keuls test was used after ANOVA. Differences between groups were considered significant at $P < 0.05$.

Results

NOS and COX activities and expression in NOD mice uteri

NOS and COX activities were significantly lower in NOD mice uteri at proestrus compared with normal BALB/c mice (Fig. 1a and c). The activity of NOS was also assayed in younger NOD and BALB/c mice (10 weeks old) and the values were found similar to normal BALB/c of 16 weeks (NOS activity in uteri from 10 weeks old NOD mice in proestrus: 125 ± 21 fmol/mg per 30 min; $n = 4$). To address whether expressional regulations of NOS and COX in uteri of NOD mice could account for the lower activity observed, the levels of the three isoforms of NOS and both isoforms of COX were determined in uteri of NOD and BALB/c mice. As it can be seen in Fig. 1b, both BALB/c and NOD mice presented the same pattern of NOS I and NOS III expression regardless of the oestrous stage studied. NOS II expression was undetectable at the same protein concentration tested for the other two isoforms. Similarly, Fig. 1d shows no significant difference in the expressions of COX-1 and COX-2 between both mice strains. To further analyze cellular localization of the isoforms of NOS first detected by immunoblotting, NOS I and NOS III, and both isoforms of COX in NOD uteri, we performed immunohistochemical studies on uterine slices. Figure 2 shows that in both NOD and normal mice, the most intense staining for NOS I was found in stromal cells and myometrial tissue, while the endothelium of both endometrial and myometrial blood vessels displayed pronounced NOS III immunostaining. COX-1 and COX-2 were distributed in both endometrial and myometrial tissue as in normal mice (data not shown).

NOS and COX activities in response to VIP

The ability of VIP to stimulate nitric oxide and prostaglandin production in mice uteri was studied at the same stages of the oestrous cycle. Figure 3 right panel shows that VIP stimulated uterine NOS activity, while decreased

Figure 1 NOS and COX activities and expressions in the uterus of NOD mice (a) Basal NOS activity was determined in uteri of NOD and BALB/c mice at different stages of the oestrous cycle as described in Materials and Methods. Estrus and metestrus values were similar to diestrus. Values represent the mean $\pm$ S.E.M. of at least six different uteri. * $P < 0.05$ vs basal value of BALB/c mice in proestrus. (b) The expression of NOS isoforms in the uteri of NOD and control mice was assessed by immunoblotting as described in Materials and Methods. Blots shown are representative of five others. NOS II isoform was undetectable in both normal and NOD uteri. Values below each blot indicate the relative intensity of each band in arbitrary density units and represent the mean $\pm$ S.E.M. of five blots. (c) Basal COX activity was determined in uteri of NOD and BALB/c mice at different stages of the oestrous cycle as described in Materials and Methods. Values represent the mean $\pm$ S.E.M. of at least five different uteri. * $P < 0.05$ vs basal value of BALB/c mice in proestrus. (d) The expression of COX isoforms in the uteri of NOD and control mice was assessed by immunoblotting as described in Materials and Methods. Blots shown are representative of four others and quantification of band intensity was similar to (b) with values indicating the mean $\pm$ S.E.M. of four blots.

prostaglandin synthesis in normal mice. In contrast, VIP failed to activate NOS or reduce prostaglandin production in NOD uteri compared with normal mice (Fig. 3 left panel). An interaction between NO and prostaglandins was further tested by performing the activity assays in the presence of VIP with or without NOS and COX inhibitors (L-NMMA and indomethacine respectively). Indomethacine failed to modify VIP-stimulated NOS activity in either mice strain (Fig. 4a), while L-NMMA reversed the inhibitory effect of VIP on PGE₂ accumulation in BALB/c mice but not in NOD mice (Fig. 4b).

Cytokine concentrations

On the knowledge that the reduced activities of both NOS and COX were evident in uteri from mice at 15–16

weeks of age in proestrus, we determined cytokine concentration in their serum at this stage. An underlying Th1 cytokine profile was evident in the sera of NOD mice, where increased levels of IL-12 and TNF- α could be observed. This profile was independent of the oestrous stage (data not shown). Serum IFN- γ levels were undetectable in both NOD and normal mice sera and IL-10 showed no changes (Table 1). Cytokine levels determined in the sera of younger 10 weeks old NOD mice did not differ from normal BALB/c values (Rosignoli *et al.* 2005). The emerging Th1 profile observed systemically at 15–16 weeks of age was not seen locally in the uteri of NOD mice, where IFN- γ and IL-10 levels were undetectable and IL-12 levels did not differ between BALB/c and NOD mice uteri (NOD IL-12 pg/mg prot.: 13.4 ± 2.8 ; $n = 4$; BALB/c: 10.0 ± 2.5 ; $n = 4$).

Figure 2 Localization of NOS in NOD mice uteri. Cellular localization of NOS I and NOS III in the uteri of NOD and control mice in proestrus was assessed by immunohistochemistry and counterstained with haematoxylin as described in Materials and Methods. Sections shown are representative of four other slices analyzed similarly, bar=20 μ m.

Discussion

We present evidence to indicate that uteri from normally cycling NOD mice display a lower activity of nitric oxide synthase and cyclo-oxygenase in basal and VIP-stimulated conditions compared with normal BALB/c mice. This functional alteration in NOD uteri is concomitant with an incipient Th1 cytokine response in the serum but not in the uterus. Our conclusions are supported by the following observations. First, NOD uteri synthesized less nitric oxide than BALB/c uteri in basal conditions in proestrus. The lower nitric oxide synthase activity of NOD uteri was not due to a lower expression or different localization of any of the isoforms of NOS. Similarly, PGE₂ production was also defective in NOD uteri and

again the effect could not be associated to a different COX-1 or COX-2 expression or localization. Second, VIP failed to stimulate nitric oxide or decrease PGE₂ production as in normal uteri and a mutual interaction between these enzymes was not seen in NOD mice. Third, NOD mice that presented these uterine signalling alterations had increased levels of IL-12 and TNF- α in their sera, but showed no significant differences in the uterine cytokine profile.

A functional interaction between progesterone, Th2 cytokines and a suitable balance between nitric oxide and prostaglandins in the uterus is considered to have a major role in the success of embryonic implantation and pregnancy (Szekeres-Bartho & Wegmann 1996, Hunt *et al.* 1997, Raghupathy 1997). Thus, embryonic resorption was associated with several conditions such as high nitric oxide and prostaglandin production in the uterus (Silver *et al.* 1995, Ogando *et al.* 2003), low progesterone levels (Elson & Jurkovic 2004) or a Th1 cytokine profile (Chaouat *et al.* 1990).

We have previously reported on a defective nitric oxide production and signalling and a lower response to VIP in secretory glands of NOD mice (Rosignoli & Perez Leiros 2002, Rosignoli *et al.* 2004). Here, we show that these defects are also present in the uterus and involve the activity of another key enzyme in reproductive tissues as COX. Both the lower activities of NOS and COX and the lower response to VIP might contribute to an up-regulation of uterine contractility and a loss of quiescence. The fact that the effects were detected in proestrus, characterized by high serum progesterone levels, suggests an additional role of this hormone in the effect. Regarding NOS and COX activities and expressions in the uterus of pregnant and non-pregnant rats, both enzymes are modulated by the progesterone levels and by the expression of progesterone receptors (Farina *et al.* 2001, 2004, Bulletti & de Ziegler 2005).

Figure 3 Effect of VIP on NO and prostaglandin production in NOD uteri. The effect of VIP (10 nM) on NOS and COX activity was assessed in uteri of NOD and BALB/c mice in proestrus and diestrus as described in Materials and Methods. Each value represents the mean $\pm$ s.e.m. of at least four determinations. * P < 0.05 vs basal values of BALB/c mice in the same oestrous stage.

Figure 4 NO and prostaglandin interaction in response to VIP. The effect of L-NMMA (500 μM) or indomethacin (1 μM) on NOS (a) and COX (b) activities in the presence of 10 nM VIP was assessed in uteri of NOD and BALB/c mice in proestrus as described in Materials and Methods. Each value represents the mean $\pm$ S.E.M. of at least four determinations. * $P < 0.05$ vs basal value of BALB/c mice, † $P < 0.01$ vs basal value of BALB/c mice and ‡ $P < 0.01$ vs VIP in BALB/c mice.

Interestingly, prostaglandin synthesis is necessary for IL-1 β -mediated stimulation of progesterone secretion in luteal cells supporting an autocrine–paracrine mechanism (Miceli *et al.* 2003).

We have also shown a systemic increase of some Th1 cytokines that was not related to the oestrous stage and occurred in NOD mice simultaneously with uterine signalling alterations: IL-12 and TNF- α , but not IFN- γ , were increased in the serum of NOD mice at 15–16 weeks of age indicating the onset of the Th1 response and confirming previous reports on the role of these two cytokines at an early time to induce autoimmunity by priming inflammatory Th1 responses (Falcone & Sarvetnick 1999). The fact that younger NOD mice (10 weeks

old) had normal NOS activity and normal cytokine levels in their serum further supports a priming role of this systemic immune response in the overall process. Progesterone can modulate cytokine levels favouring a Th2 profile (Szekeres-Bartho & Wegmann 1996, Raghupathy 1997). Interestingly, it reduces IL-12 expression through the inhibition of arachidonic acid metabolism (Par *et al.* 2000). However, the converse has not been fully clarified as cytokines probably interact with progesterone synthesis in a systemic and more complex manner (Bornstein *et al.* 2004). Reports on Th1 autoimmune diseases like rheumatoid arthritis indicate that serum progesterone levels do not vary compared with normal subjects or were found decreased with a consequent decrease of the free androgen index (Valentino *et al.* 1993, Olsen & Kovacs 2002, Rovinsky *et al.* 2004, 2005). Regarding Sjögren's syndrome, no significant differences were observed in the levels of oestrogen and progesterone in sera between patients and controls although a higher oestrogen:progesterone relative ratio was reported (Taiym *et al.* 2004). Of interest, a lower progesterone concentration in the serum of prediabetic NOD mice has been observed when compared with normal control strains (Durant *et al.* 1998). It should be emphasized that not only the levels of circulating hormones but the expression and signalling through their receptors can be also rapidly regulated by changes in the immune–hormonal milieu during the course of chronic autoimmune disorders with such multifactorial origin.

With the aim of further analyzing the mechanism of NOS- and COX-deficient activities in NOD uteri, we explored the cellular localization of both enzymes in uterine tissue as well as the regulatory interaction between these enzymes and the local expression of cytokines in the tissue. Both NOS and COX isoforms were expressed in uteri to the same extent regardless of the oestrous stage or the level of activity displayed. Moreover, the enzymes presented a localization and immunostaining pattern comparable with normal mice and similar to other species. Taken together, these results rule out an expressional regulation of their activity (Chatterjee *et al.* 1996, Andronowska *et al.* 2005). Regarding the mutual regulation of their activities by the products of each other, we provided evidence of an interaction between NOS and COX in response to VIP that is not present in NOD mice. Neither the loss of enzyme activity, nor the regulatory failure seemed to be related to the local production of cytokines in uterine tissues, since there were no changes in their local levels. Moreover, uteri from younger NOD mice presented a normal pattern of NOS activity and expression when their serum levels of Th1 cytokines were still low. Accordingly, the increase of Th1 cytokines parallels the onset of uterine signalling alterations supporting a priming role of these mediators by means of a systemic rather than local effect. Although the mechanisms

Table 1 Serum levels of cytokines.

	Cytokines (pg/ml)			
	IL-12	TNF- α	IL-10	IFN- γ
NOD	182 $\pm$ 11*	223 $\pm$ 21*	142 $\pm$ 23	ND
BALB/c	102 $\pm$ 17	104 $\pm$ 5	152 $\pm$ 12	ND

Freshly isolated serum from each animal was individually processed and aliquoted for cytokine determination by a sandwich ELISA kit as described in Materials and Methods. No differences in cytokine levels were found between cycle stages in neither NOD nor BALB/c mice. Values are the mean $\pm$ S.E.M. of at least five different sera from NOD or BALB/c mice. * $P < 0.05$ vs. BALB/c. ND, undetectable.

underlying these cellular and signalling alterations in NOD mice are not clarified at present, the ultimate effects of these alterations combined would be a loss of uterine quiescence that in turn would affect implantation and pregnancy. Further evidence will be necessary to assess if the differential serum cytokine profile in NOD mice at 15–16 weeks of age could account for NOS and COX defects in uterine tissues and if so, how this could influence NOD reproductive scores at later stages of disease. Also, a role of lower serum progesterone concentration in the onset of uterine and immune alterations in NOD mice should be further analyzed. A cross-talk between the immune and neuroendocrine systems might have a role in the loss of homeostatic control that precedes autoimmune diseases like Sjögren's syndrome. However, multiple immune-hormonal loops acting simultaneously and redundantly hinder the identification of individual effects of hormones and cytokines.

Finally, VIP might be an interesting immune-neuroendocrine mediator in this system as a modulator of the immune response through its selective anti-inflammatory action on lymphocytes and macrophages on one side (Delgado *et al.* 2002), and the down-regulatory effect on uterus contractility through prostaglandin-mediated pathways on the other (Ottesen *et al.* 1982). VIP levels vary in the uterus and deciduas at the early phases of implantation, and it has been assigned a role as a neural growth factor for the embryos (Gressens *et al.* 1998, Spong *et al.* 1999). In the light of these reports and the observations described here, it is conceivable that a defective VIP response in the uterus and/or the surrounding immune cells could result in a defective conditioning for successful implantation and pregnancy. The association of serum cytokine levels with biochemical alterations in uterine tissues as those reported here and the identification of the mechanisms underlying such functional interaction might be relevant for pregnancy in several immunopathological conditions as well as for the management of women with frequent miscarriage.

Acknowledgements

This work was supported by grants PICT 10901 from the ANPCyT and PIP 5638 from CONICET, Argentina. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References

Andronowska A, Wasowska B, Calka J & Doboszynska T 2005 Localization and correlation between NADPH-diaphorase and nitric oxide synthase isoforms in the porcine uterus during the estrous cycle. *Cell and Tissue Research* **321** 243–250.

- Bornstein SR, Rutkowski H & Vrezas I 2004 Cytokines and steroidogenesis. *Molecular and Cellular Endocrinology* **215** 135–141.
- Bulletti C & de Ziegler D 2005 Uterine contractility and embryo implantation. *Current Opinion in Obstetrics & Gynecology* **17** 265–276.
- Cella M, Aisemberg J, Sordelli MS, Billi S, Farina M, Franchi AM & Ribeiro ML 2006 Prostaglandins modulate nitric oxide synthase activity early in time in the uterus of estrogenized rat challenged with lipopolysaccharide. *European Journal of Pharmacology* **534** 218–226.
- Chaouat G, Menu E, Clark DA, Dy M, Minkowski M & Wegmann TG 1990 Control of fetal survival in CBA x DBA/2 mice by lymphokine therapy. *Journal of Reproduction and Fertility* **89** 447–458.
- Chatterjee S, Gangula PR, Dong YL & Yallampalli C 1996 Immunocytochemical localization of nitric oxide synthase-III in reproductive organs of female rats during the oestrous cycle. *Histochemical Journal* **28** 715–723.
- Chwalisz K & Garfield RE 2000 Role of nitric oxide in implantation and menstruation. *Human Reproduction* **3** 96–111.
- Chwalisz K, Buhimschi I & Garfield RE 1996 Role of nitric oxide in obstetrics. *Prenatal and Neonatal Medicine* **1** 292–328.
- Chwalisz K, Winterhager E, Thienel T & Garfield RE 1999 Synergistic role of nitric oxide and progesterone during the establishment of pregnancy in the rat. *Human Reproduction* **14** 542–552.
- Clark KE, Mills EG, Stys SJ & Seeds AE 1981 Effects of vasoactive polypeptides on the uterine vasculature. *American Journal of Obstetrics and Gynecology* **139** 182–188.
- Cutolo M 2000 Sex hormone adjuvant therapy in rheumatoid arthritis. *Rheumatic Diseases Clinics of North America* **26** 881–895.
- Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, Gomariz RP & Leceta J 2002 Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. *Journal of Molecular Medicine* **80** 16–24.
- Durant S, Christeff N, Coulaud J, Nunez EA, Dardenne M & Homodelarche F 1998 Basal concentrations of various steroids in the nonobese diabetic (NOD) Mouse and effect of immobilization stress. *Autoimmunity* **28** 249–258.
- Ekström J, Mansson B & Tobin G 1983 Vasoactive intestinal peptide evokes secretion of fluid and protein from rat salivary glands and the development of hypersensitivity. *Acta Physiologica Scandinavica* **119** 169–175.
- Elson J & Jurkovic D 2004 Biochemistry in diagnosis and management of abnormal early pregnancy. *Current Opinion in Obstetrics & Gynecology* **16** 339–344.
- Falcone M & Sarvetnick N 1999 Cytokines that regulate autoimmune responses. *Current Opinion in Immunology* **11** 670–676.
- Farina M, Ribeiro ML & Franchi A 2001 Nitric oxide synthases in pregnant rat uterus. *Reproduction* **121** 403–407.
- Farina M, Ribeiro ML, Weissmann C, Estevez A, Billi S, Vercelli C & Franchi A 2004 Biosynthesis and catabolism of prostaglandin F₂alpha (PGF₂alpha) are controlled by progesterone in the rat uterus during pregnancy. *Journal of Steroid Biochemistry and Molecular Biology* **91** 211–218.
- Gressens P, Païndaveine B, Hill JM, Evrard P & Brennehan DE 1998 Vasoactive intestinal peptide shortens both G1 and S phases of neural cell cycle in whole postimplantation cultured mouse embryos. *European Journal of Neuroscience* **10** 1734–1742.
- Hunt JS, Miller L, Vassmer D & Croy BA 1997 Expression of the inducible nitric oxide synthase gene in mouse uterine leukocytes and potential relationships with uterine function during pregnancy. *Biology of Reproduction* **57** 827–836.
- Inoue Y, Kaku K, Kaneko T, Yanahara N & Kanno T 1985 Vasoactive intestinal peptide binding to specific receptors on rat parotid acinar cells induces amylase secretion accompanied by cyclic adenosine 3'-5'-monophosphate. *Endocrinology* **116** 686–692.
- Jaffe BM & Behrman HR 1974 *Methods of Hormone Radioimmunoassay*, New York, USA: Academic Press.

- Jovanovic A, Jovanovic S, Tulic I & Grbovic L 1998 Predominant role for nitric oxide in the relaxation induced by vasoactive intestinal polypeptide in human uterine artery. *Molecular Human Reproduction* **4** 71–76.
- Juarranz MG, Santiago B, Torroba M, Gutierrez-Cañas I, Palao G, Galindo M, Abad C, Martinez C, Leceta J, Pablos JL & Gomariz RP 2004 Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. *Rheumatology* **43** 416–422.
- MacMicking J, Xie QW & Nathan C 1997 Nitric oxide and macrophage function. *Annual Review of Immunology* **15** 323–350.
- Miceli F, Tropea A, Minici F, Navarra P, Lanzone A & Apa R 2003 Interleukin-1 beta stimulates progesterone production by *in vitro* human luteal cells: evidence of a mediatory role of prostaglandins. *Journal of Clinical Endocrinology and Metabolism* **88** 2690–2694.
- Moncada S, Palmer RMJ & Higgs EA 1991 Nitric oxide physiology, pathophysiology and pharmacology. *Pharmacological Reviews* **43** 109–142.
- Murthy KS, Zhang KM, Jin JG, Grider JR & Makhlof GM 1993 VIP-mediated G protein-coupled Ca²⁺ influx activates a constitutive NOS in dispersed gastric muscle cells. *American Journal of Physiology* **265** G660–G671.
- Nelson JL & Ostensen M 1997 Pregnancy and rheumatoid arthritis. *Rheumatic Diseases Clinics of North America* **23** 195–212.
- Ogando DG, Paz D, Cella M & Franchi AM 2003 The fundamental role of increased production of nitric oxide in lipopolysaccharide-induced embryonic resorption in mice. *Reproduction* **125** 95–110.
- Olsen NJ & Kovacs WJ 2002 Hormones, pregnancy, and rheumatoid arthritis. *Journal of Gender-Specific Medicine* **5** 28–37.
- Ota H, Igarashi S, Oyama N, Suzuki Y & Tanaka T 1999 Optimal levels of nitric oxide are crucial for implantation in mice. *Reproduction, Fertility, and Development* **11** 183–188.
- Ottesen B, Ulrichsen H, Fahrenkrug J, Larsen JJ, Wagner G, Schierup L & Sondergaard F 1982 Vasoactive intestinal polypeptide and the female genital tract: relationship to reproductive phase and delivery. *American Journal of Obstetrics and Gynecology* **143** 414–420.
- Par G, Bartok B & Szekeres-Bartho J 2000 Cyclooxygenase is involved in the effects of progesterone-induced blocking factor on the production of interleukin 12. *American Journal of Obstetrics and Gynecology* **183** 126–130.
- Purcell TL, Given R, Chwalisz K & Garfield RE 1999 Nitric oxide synthase distribution during implantation in the mouse. *Molecular Human Reproduction* **5** 467–475.
- Raghupathy R 1997 Th1-type immunity is incompatible with successful pregnancy. *Immunology Today* **18** 478–482.
- Ribeiro ML, Cella M, Farina M & Franchi A 2003 Crosstalk between nitric oxide synthase and cyclooxygenase metabolites in the estrogenized rat uterus. *Prostaglandins, Leukotrienes, and Essential Fatty Acids* **4** 285–290.
- Robinson CP, Yamamoto H, Peck AB & Humphreys-Beher MG 1996 Genetically programmed development of salivary gland abnormalities in the NOD (non obese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice. *Clinical Immunology and Immunopathology* **79** 50–59.
- Rosignoli F & Perez Leiros C 2002 Nitric oxide synthase I and VIP-activated signaling are affected in salivary glands of NOD mice. *Journal of Neuroimmunology* **130** 109–116.
- Rosignoli F, Roca V, Meiss R, Pregi N & Pérez Leirós C 2004 Inhibition of calcium-calmodulin kinase restores nitric oxide production and signaling in submandibular glands of a mouse model of salivary dysfunction. *British Journal of Pharmacology* **143** 1058–1065.
- Rosignoli F, Roca V, Meiss R, Leceta J, Gomariz RP & Pérez Leirós C 2005 Defective signalling in salivary glands precedes the autoimmune response in the non-obese diabetic mouse model of sialadenitis. *Clinical and Experimental Immunology* **142** 411–418.
- Rovensky J, Radikova Z, Imrich R, Greguska O, Vígás M & Macho L 2004 Gonadal and adrenal steroid hormones in plasma and synovial fluid of patients with rheumatoid arthritis. *Endocrine Regulations* **38** 143–149.
- Rovensky J, Kvetnansky R, Radikova Z, Imrich R, Greguska O, Vígás M & Macho L 2005 Hormone concentrations in synovial fluid of patients with rheumatoid arthritis. *Clinical and Experimental Rheumatology* **23** 292–296.
- Silver RM, Edwin SS, Trautman MS, Simmons DL, Branch DW, Dudley DJ & Mitchell MD 1995 Bacterial lipopolysaccharide-mediated fetal death. Production of a newly recognized form of inducible cyclooxygenase (COX-2) in murine decidua in response to lipopolysaccharide. *Journal of Clinical Investigation* **95** 725–731.
- Spong CY, Lee SJ, McCune SK, Gibney G, Abebe DT, Alvero R, Brennen DE & Hill JM 1999 Maternal regulation of embryonic growth: the role of vasoactive intestinal peptide. *Endocrinology* **140** 917–924.
- Szekeres-Bartho J 2002 Immunological relationship between the mother and the fetus. *International Reviews of Immunology* **21** 471–495.
- Szekeres-Bartho J & Wegmann TG 1996 A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. *Journal of Reproductive Immunology* **31** 81–95.
- Taiym S, Haghighat N & Al-Hashimi I 2004 A comparison of the hormone levels in patients with Sjogren's syndrome and healthy controls. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics* **97** 579–583.
- Valentino R, Savastano S, Tommaselli AP, Riccio A, Mariniello P, Pronesti G, De Divitiis PM & Lombardi G 1993 Hormonal pattern in women affected by rheumatoid arthritis. *Journal of Endocrinological Investigation* **16** 619–624.
- van Blokland SC & Versnel MA 2002 Pathogenesis of Sjogren's syndrome: characteristics of different mouse models for autoimmune exocrinopathy. *Clinical Immunology* **103** 111–124.
- Wang H & Dey SK 2005 Lipid signaling in embryo implantation. *Prostaglandins & Other Lipid Mediators* **77** 84–102.
- Zhang X, Wang HM, Lin HY, Liu GY, Li QL & Zhu C 2004 Regulation of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) during mouse peri-implantation: role of nitric oxide. *Placenta* **25** 243–252.

Received 18 November 2005

First decision 11 January 2006

Revised manuscript received 16 May 2006

Accepted 26 June 2006